MannKind Co. (MNKD) Receives Consensus Rating of “Hold” from Brokerages
MannKind Co. (NASDAQ:MNKD) has received an average recommendation of “Hold” from the eight analysts that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $0.92.
Several research firms have recently commented on MNKD. Zacks Investment Research raised MannKind from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. HC Wainwright began coverage on MannKind in a report on Tuesday, October 10th. They set a “buy” rating for the company. ValuEngine lowered MannKind from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Maxim Group reaffirmed a “hold” rating on shares of MannKind in a report on Wednesday, November 1st. Finally, BidaskClub lowered MannKind from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd.
In related news, VP Stuart A. Tross bought 39,840 shares of the stock in a transaction dated Thursday, December 21st. The stock was bought at an average cost of $2.52 per share, with a total value of $100,396.80. Following the completion of the acquisition, the vice president now owns 59,840 shares of the company’s stock, valued at $150,796.80. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.10% of the stock is currently owned by corporate insiders.
Shares of MannKind (NASDAQ MNKD) opened at $2.51 on Thursday. MannKind has a one year low of $0.67 and a one year high of $6.96. The stock has a market capitalization of $288.33, a P/E ratio of -9.30 and a beta of 3.08. The company has a current ratio of 0.31, a quick ratio of 0.28 and a debt-to-equity ratio of -0.43.
MannKind (NASDAQ:MNKD) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.11). The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.56 million. MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%. The firm’s revenue for the quarter was down 98.7% compared to the same quarter last year. During the same period last year, the company posted $1.30 earnings per share. equities research analysts expect that MannKind will post -1.13 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “MannKind Co. (MNKD) Receives Consensus Rating of “Hold” from Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/18/mannkind-co-mnkd-receives-consensus-rating-of-hold-from-brokerages.html.
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.